Searchable abstracts of presentations at key conferences in endocrinology

ea0098t12 | Trials In Progress | NANETS2023

Neuroendocrine tumors AI-based clinical trial search tool eases clinical trial discovery for patients and health care professionals

Mailman Josh , Ralic Danielle , del Rivero MD Jaydira , Gericke MD Germo , Halfdanarson MD Thorvardur R. , Herrmann MD Ken , Hollander Ronald , Albert Fisher Jr. MD George

Background: Finding relevant neuroendocrine tumor (NET) trials remains a challenge for patients and healthcare professionals (HCPs). Clinicaltrials.gov’s taxonomy associates many conditions with NETs, complicating the discovery process. As of 6/30/23 clinicaltrials.gov listed 700 recruiting, phase 1-3 interventional trials using the terms Neuroendocrine Tumors, Pheochromocytoma, and Paraganglioma. Many of these trials are not relevant for patients with NETs. Even with sev...

ea0089c16 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Clinical Utility of Somatostatin Receptor Positron Emission Tomography Imaging Biomarkers for Characterization of Meningioma Among Incidental Central Nervous System Lesions

Fortin Ensign, MD, PhD Shannon , Agarwal, MD Muskan , Klanderman, PhD Molly , Badawy, MB, BCh Mohamed , Halfdanarson, MD Thorvardur R. , Johnson, MD Derek R. , Bassam Sonbol, MD Mohamad , Kendi, MD Ayse T.

Background: Somatostatin receptor (SSTR) PET imaging is utilized with increasing frequency in the clinical management of neuroendocrine tumors. Incidental PET-avid CNS lesions are commonly noted and presumed to be meningiomas. However, SSTR PET lacks specificity for meningioma identification. This study aims to clarify the role of SSTR-based imaging for classification of incidental CNS lesionsMethods: Patients who had undergone both Ga-68-DOTATATE PET an...

ea0098c11 | Clinical – Chemo/SSA/Biologics | NANETS2023

Transformation of low-intermediate grade neuroendocrine tumors into high grade morphology

McGlothlin, MD John D. , Dilmaghani, MD Saam , Hazim, MD Antonious Z. , Hobday, MD Timothy J. , Sonbol, MD Mohamad B. , Starr, DO Jason S. , Eiring, PA-C Rachel A. , Graham MBBS Rondell P. , Halfdanarson, MD Thorvardur R.

Background: Low- (G1) and intermediate-grade (G2) neuroendocrine tumors (NET) are defined by lower mitotic rates and genetic mutations that rarely cause transformation to high-grade (G3) neoplasm. Yet a proportion of patients with de novo low-grade NETs progress to G3 disease or even neuroendocrine carcinoma (NEC). We aimed to highlight cases of low-grade G1 and G2 NETs that eventually transformed to G3 pathology on repeat biopsy and describe characteristics that portend high-...

ea0089c21 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2022

Characterizing Bone Metastases in Patients with Well-Differentiated Neuroendocrine Neoplasms Utilizing Ga68-DOTATATE PET

Coston, MD Tucker W. , Mahadevia, MBBS Himil J. , Plante, MD Marie M. , Accurso, MD Joseph M. , Sharma, MD, MBA Akash , Johnson, MD, PhD Geoffrey B. , Ashman, MD, PhD Jonathan B. , Tuba Kendi, MD Ayse , Bassam Sonbol, MD Mohamad , Hobday, MD Timothy J. , Halfdanarson, MD Thorvardur R. , Starr, DO Jason S.

Background: Tumors of neuroendocrine origin are a rare, heterogenous group of neoplasms. Neuroendocrine neoplasms (NENs) are categorized by site of origin, differentiation status, and by grade (Ki-67 expression and/or mitotic rate), with significant prognostic variability accordingly. These tumors frequently metastasize to bone, with reported incidence between 6-12% by older SSTR imaging. Our study evaluates patients with well-differentiated tumors of neuroendocrine origin to ...

ea0098c43 | Clinical – Surgery/Applied Pathology | NANETS2023

Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection

Zhang, MD Chi , Gudmundsdottir, MD Hallbera , Takahashi, MD, PhD Hiroaki , Day, MS Courtney , Glasgow, MHA Amy , Wasif, MD, MPH Nabil , Starlinger, MD Patrick , Warner, MD Susanne , Grotz, MD Travis , Smoot, MD Rory , Truty, MD Mark , Cleary, MD Sean , Kendrick, MD Michael , Nagorney, MD David , Navin, MB, BCh Patrick , Halfdanarson, MD Thorvardur R. , Thiels, DO, MBA Cornelius

Background: Small bowel neuroendocrine tumors (sbNETs) incidence is on the rise. Given that sbNETS are often multifocal with high risk of regional nodal metastasis, open resection with lymphadenectomy is the gold standard approach as it offers manual palpation of the entire small bowel. We evaluated the accuracy of preoperative DOTATATE PET/CT in estimating the number of lesions and the presence of nodal disease compared to postoperative pathology findings. We hypothesize that...